Janux Therapeutics, Inc. (JANX)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$31.81

P/E Ratio

N/A

Market Cap

$1.88B

Loading...
Description
Add to research

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Metrics
Add to research

Overview

  • HQSan Diego, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerJANX
  • Price$31.81+8.75%

Trading Information

  • Market cap$1.88B
  • Float83.21%
  • Average Daily Volume (1m)952,619
  • Average Daily Volume (3m)981,535
  • EPS-$1.28

Company

  • Revenue$10.59M
  • Rev growth (1yr)30.99%
  • Net income-$68.99M
  • Gross margin80.54%
  • EBITDA margin-914.12%
  • EBITDA-$96.79M
  • EV$1.88B
  • EV/Revenue177.15
  • P/EN/A
  • P/S161.49
  • P/B1.84
  • Debt/Equity2.25
Documents
Add to research